Moffitt Start-up Wins Biopitch Competition at BioFlorida Conference

November 01, 2017

TAMPA, Fla.Interpares Biomedicine, an early-stage immuno-oncology company founded by Moffitt Cancer Center faculty member Howard McLeod, PharmD was named the 2017 BioPitch Competition winner at BioFlorida’s annual conference. The company was founded by McLeod and a member of his team, Neil T. Mason, using their own funds. Together with Moffitt’s Jamie Teer, Ph.D. and seasoned biotech executive Kevin Krenitsky, M.D. they have created a suite of diagnostic tools designed to help physicians match the best immunotherapy drugs to an individual patient. 

“Cancer treatment is moving away from a one size fits all to a more personalized approach. Interpares aims to create tools physicians can use to match the best therapy or drug to a patient based on their cancer and genetic makeup,” said McLeod. “This ensures a patient has the maximum benefit with limited toxicity.” Interpares has focused on providing personalized medicine solutions for cancer immunotherapy.  This includes a number of diagnostic, prognostic, predictive, and therapeutic strategies to better understand a patient’s likelihood of both benefit and risk from the distinct types of immunotherapy. 

Interpares Biomedicine was one of over 40 companies that applied for the BioPitch competition. BioFlorida selected 15 seed and early-stage life science companies to compete. The companies presented to investors during a closed-door session. Four were selected as finalists and invited to present in open session to a panel of investors during BioFlorida’s annual conference, where Interpares was named the winner. 

About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, clinical trials, prevention and cancer control. Moffitt is listed as one of the top 10 cancer hospitals in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,600 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube

###